EGRIFTA™ (Tesamorelin for Injection) Approved in Mexico
MONTREAL, CANADA--(Marketwired - July 14, 2015) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) is pleased to announce that COFEPRIS, Mexico's health agency, has approved the 2mg/vial presentation of tesamorelin for the treatment of lipodystrophy. Theratechnologies' partner, sanofi, will re-submit a file to COFEPRIS to seek approval of the 1mg/vial presentation of EGRIFTA which is the one currently marketed in other territories. As was the case with Canada, the commercialization of EGRIFTA in Mexico will be initiated upon obtaining approval of the 1mg/vial presentation. "We are very pleased with COFEPRIS' decision. We view Mexico as the cornerstone of Latin America for EGRIFTA and we are proud that EGRIFTA may soon be available to the Latin American population," said Luc Tanguay, President and CEO, Theratechnologies Inc. EGRIFTA was first approved by the United States Food and Drug Administration in November 2010 and was recently approved in March 2015 by Health Canada. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and an improved quality of life. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com